The BSTH database of special haemostasis assays offers an informative tool to allow colleagues active in the field of coagulation and haemostasis to localise the special tests available in Belgian laboratories.
If you want to add your lab and/or more tests please contact Christelle.Orlando@uzbrussel.be from the Working group BSTH Database Special Coagulation Assays.
| Brugmann | UZA | UZ Brussel | ULg | UZ Gent | UZ Leuven | CHR Citadelle | CMG Gent | AZ St. Jan | CHU Charleroi | CHU UCL Namur | KULAK | UCL Genetics | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADAMTS-13 activity |
 |
|
|
|
|
||||||||
| ADAMTS-13 antigen |
|
|
|||||||||||
| ADAMTS-13 inhibitor |
|
|
|||||||||||
| Aggregometry (LTA) |
|
|
|
|
|||||||||
| Aggregometry (LTA) and platelet secretion |
|
|
|
|
|
|
|||||||
| Aggregometry whole blood (WBA) by Multiplate |
|
|
|
|
|||||||||
| Alfa 1 antiplasmin |
|
|
|
||||||||||
| AntiXa activity (UFH, LMWH) |
|
|
|
|
|
|
|
||||||
| AntiXa activity (UFH, LMWH, Orgaran) |
|
|
|
|
|
||||||||
| Antibeta2glycoprotein I antibodies |
|
|
|
|
|
||||||||
| Antithrombin antigen |
|
||||||||||||
| Antithrombin mutation analysis |
|
||||||||||||
| Direct anti-IIa inhibitor (dabigatran) monitoring |
|
|
|
|
|
|
|
||||||
| Direct anti-IIa inhibitor (hirudin) monitoring |
|
|
|||||||||||
| Direct anti-Xa inhibitors (apixaban) monitoring |
|
|
|
||||||||||
| Direct anti-Xa inhibitors (edoxaban) |
|
|
|
||||||||||
| Direct anti-Xa inhibitors (rivaroxaban) monitoring |
|
|
|
|
|
|
|
|
|||||
| Euglobuline lysis time |
|
|
|
|
|||||||||
| FXIII activity |
|
|
|||||||||||
| FXIII quantitative antigen |
|
|
|
|
|
||||||||
| Fibronectin |
|
||||||||||||
| Fondaparinux |
|
|
|||||||||||
| HIT antibodies functional test |
|
|
|
||||||||||
| HIT antibodies immunological test |
|
|
|
|
|
|
|
||||||
| Homocystiniurea, MTHFR |
|
||||||||||||
| Mutation PROS1 Protein S (alpha) deficiency |
|
||||||||||||
| Mutation analysis Hemophilia A |
|
||||||||||||
| Mutation analysis Hemophilia B |
|
||||||||||||
| Mutation screening ADAMTS13 |
|
||||||||||||
| Mutation screening GPIIbIIIa |
|
||||||||||||
| Mutation screening GPIb |
|
||||||||||||
| Mutation screening VWF |
|
|
|||||||||||
| PAI |
|
|
|||||||||||
| Platelet disorders special tests |
|
|
|
||||||||||
| Protein C mutation analysis |
|
||||||||||||
| Quantification specific coagulation inhibitors |
|
|
|
|
|
|
|||||||
| Reptilase time |
|
|
|||||||||||
| SRY (Sex-determining region Y) |
|
||||||||||||
| Thrombin generation |
|
|
|
|
|||||||||
| Thrombin-antithrombin complexes |
|
|
|||||||||||
| Thromboelastrogram (ROTEM) |
|
|
|
||||||||||
| Thrombotest |
|
|
|||||||||||
| tPA |
|
|
|||||||||||
| vWF multimers |
|
|
|
|
|||||||||
| vWF propeptide |
|
||||||||||||
| vWF-FVIII binding |
|
|
|||||||||||
| vWF: collagen Binding assay |
|
|
|
|
|